Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Aminoglycosides Market Size & Share 2026-2035
Report ID: GMI13029
|
Published Date: November 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Aminoglycosides Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Aminoglycosides Market Size
The global aminoglycosides market was valued at USD 1.92 billion in 2025, is projected to reach USD 2.0 billion in 2026, and is expected to expand at a 3.5% CAGR from 2026 to 2035, reaching USD 2.73 billion by 2035.
Aminoglycosides Market Key Takeaways
Market Leader: Fresenius Kabi led with over 13.8% market share in 2025.
Leading Players: Top 5 players in this market include Fresenius Kabi, Pfizer, Aurobindo Pharma, Novartis (Sandoz), Cipla, which collectively held a market share of 43.0% in 2025.
The aminoglycosides market remains anchored in institutional treatment of gram-negative infections, where rapid bactericidal activity and low-cost generic availability preserve formulary relevance. Revenue growth will depend less on broad-based volume expansion than on the evolving mix of resistant-pathogen treatment, inhaled formulations, public-health procurement, and clinical monitoring capacity.
GMI Analyst View
Based on our aggregated analysis of pharmaceutical procurement and channel-level sales data across primary markets, we estimate that the global aminoglycosides market generated USD 1.71 billion in revenue in 2022. We view this historic base as evidence of a durable institutional demand floor, with hospital treatment protocols and public procurement continuing to support the class despite selective therapeutic substitution.
Aminoglycosides Market Trends, Growth Drivers & GMI Forecast Outlook
Persistent gram-negative infection pressure and endemic tuberculosis sustain baseline demand, while stewardship frameworks preserve defined roles for individual products. The forecast is moderated by safety constraints, increasingly oral drug-resistant tuberculosis protocols, and the operational limits that monitoring requirements place on use outside specialist care.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Tuberculosis procurement remains concentrated in high-incidence markets, making the class sensitive to treatment-program design rather than to uniform global prescribing trends. Where longer regimens remain clinically necessary or operationally accessible, amikacin and streptomycin retain a role in public-sector supply. This creates a durable but geographically concentrated demand pool, particularly for suppliers able to meet national tender requirements and maintain dependable injectable availability.
Hospital treatment of resistant gram-negative infections provides a separate demand base. Aminoglycosides retain value where rapid bactericidal activity, susceptibility results, combination-treatment protocols, and carbapenem-sparing objectives align. Their role is increasingly shaped by stewardship governance: formulary committees can preserve use in defined clinical pathways while limiting indiscriminate prescribing.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
The shift toward all-oral drug-resistant tuberculosis treatment changes the composition of public procurement. It does not eliminate aminoglycoside demand across tuberculosis care, but it reduces the clinical settings in which injectable products are routine and increases exposure to national guideline updates. Streptomycin is especially vulnerable to this transition, while amikacin retains a more selective role where treatment choices remain constrained.
Monitoring capacity is an equally important commercial constraint. The narrow therapeutic index of aminoglycosides makes serum-level monitoring, renal assessment, and pharmacy oversight material to prescribing confidence. In settings without those capabilities, clinicians and formularies may restrict treatment to tertiary facilities, limiting the extent to which infection burden converts into addressable demand.
GMI Analyst View
We see the market developing along two diverging clinical pathways: hospital-based gram-negative infection management is preserving a steady utilization floor, whereas oral treatment protocols are reducing the historic importance of injectable tuberculosis therapy. The implication is a progressively more differentiated portfolio, in which formulation, monitoring compatibility, and resistant-pathogen positioning matter more than undifferentiated generic volume.
Aminoglycosides Market Segment Analysis
By Product
Gentamicin
Gentamicin generated USD 576 million in 2025 and is expected to retain a 29.8% share by 2035. Within the aminoglycosides market, its broad role in hospital empiric treatment, ophthalmic preparations, and first-line institutional protocols supports category leadership, although sterile-injectable price pressure and supply continuity remain central determinants of manufacturer performance.
Tobramycin
Tobramycin generated USD 422 million in 2025 and is projected to grow at a 3.8% CAGR (2026-2035). Demand is supported by its differentiated role in Pseudomonas-focused hospital care and inhaled therapy, giving the product exposure to specialty respiratory treatment as well as conventional injectable procurement.
Amikacin
Amikacin held an 18.0% share in 2025 and is projected to generate USD 506 million by 2035. Its value lies in use against serious resistant gram-negative infections, where lower treatment volumes are offset by ICU-oriented clinical demand and its continuing, though narrower, role in selected tuberculosis pathways.
Streptomycin
Streptomycin generated USD 154 million in 2025 and is projected to grow at a 1.3% CAGR (2026-2035). The product remains relevant to selected tuberculosis and other infectious-disease protocols, but all-oral regimen adoption and resistance-related treatment changes limit its forward commercial scope.
Neomycin
Neomycin is projected to generate USD 257 million by 2035 and held a 10.0% share in 2025. Its demand profile is predominantly non-systemic, supported by topical products, ophthalmic formulations, bowel preparation, and other applications where limited systemic absorption is commercially and clinically advantageous.
Paromomycin
Paromomycin is projected to generate USD 142 million by 2035 and grow at a 4.0% CAGR (2026-2035). The product occupies a specialized position in leishmaniasis control and intestinal infection treatment, with demand shaped by endemic-disease procurement programs and cost-sensitive public-health channels.
Other Products
Other products are expected to hold an 8.2% share by 2035 and grow at a 5.2% CAGR (2026-2035). This category captures the class's most differentiated development opportunities, including modified aminoglycosides and therapies designed to retain activity against resistant pathogens or serve narrower specialist indications.
By Application
Bacterial Infection
Bacterial infection generated USD 1.15 billion in 2025 and is expected to account for 62.0% of total revenue by 2035. The application remains the commercial core of the aminoglycosides market because hospital management of gram-negative infections spans acute respiratory, bloodstream, urinary, and surgical settings where formulary-directed use remains clinically established.
Respiratory Infections
Respiratory infections generated USD 422 million in 2025 and are projected to grow at a 4.0% CAGR (2026-2035). Inhaled tobramycin and hospital treatment of resistant respiratory infections create distinct demand streams, combining recurring specialist-care use with acute-care consumption.
Skin & Soft Tissue Infections
Skin & soft tissue infections are projected to generate USD 326 million by 2035 and held a 12.0% share in 2025. Topical neomycin formulations underpin broad retail and wound-care use, while injectable aminoglycosides retain a more selective institutional role in severe culture-confirmed infections.
Bone & Joint Infections
Bone & joint infections held an 8.0% share in 2025 and are projected to generate USD 219 million by 2035. Local antibiotic delivery, including aminoglycoside-containing orthopedic materials, supports a clinically defensible niche in surgical prophylaxis and management of difficult-to-treat infection.
UTIs
UTIs are projected to generate USD 524 million by 2035 and grow at a 4.2% CAGR (2026-2035). Resistant complicated urinary infections provide the principal growth opportunity, particularly where susceptibility profiles allow aminoglycosides to serve as parenteral, carbapenem-sparing treatment options.
Tuberculosis
Tuberculosis is projected to generate USD 574 million by 2035 and grow at a 1.8% CAGR (2026-2035). Demand remains tied to high-burden public-health programs and residual injectable regimens, but treatment modernization is steadily shifting procurement toward more selective use cases.
Other Applications
Other applications are expected to hold a 17.0% share by 2035 and grow at a 4.9% CAGR (2026-2035). Leishmaniasis, endocarditis combination therapy, surgical prophylaxis, and protozoal infections broaden the demand base and give this category greater insulation from any single infectious-disease treatment transition.
By Route of Administration
Oral
Oral products generated USD 672 million in 2025 and are expected to hold a 35.1% share by 2035. Non-systemically absorbed formulations, especially those used in gastrointestinal indications and bowel preparation, provide a stable demand base distinct from acute-care injectable consumption.
Injectable
Injectable products held a 33.0% share in 2025 and are projected to grow at a 3.3% CAGR (2026-2035). This route remains clinically indispensable for high-acuity treatment, but supplier qualification, sterile-manufacturing resilience, monitoring requirements, and hospital formulary decisions shape its revenue realization.
Topical
Topical products are projected to generate USD 575 million by 2035 and grow at a 4.1% CAGR (2026-2035). Demand is led by neomycin-containing preparations in community pharmacy and wound-care settings, where branded-generic reach and local channel access influence competitive outcomes.
Ophthalmic
Ophthalmic products are projected to generate USD 323 million by 2035 and held a 12.0% share in 2025. The segment combines routine retail demand for bacterial eye conditions with institutional use around ophthalmic procedures, providing a steadier profile than many systemic applications.
By End Use
Hospitals & Clinics
Hospitals & clinics generated USD 1.38 billion in 2025 and are expected to account for 71.8% of the market by 2035. Institutional dominance reflects the need for culture-guided prescribing, parenteral administration, renal monitoring, and antimicrobial-stewardship oversight in the class's highest-value indications.
Research & Academic Institutes
Research & academic institutes are projected to generate USD 141 million by 2035 and grow at a 3.9% CAGR (2026-2035). Demand includes antimicrobial research, pharmacokinetic work, clinical trials, and the stewardship activities of academic medical centers.
Homecare Settings
Homecare settings are projected to generate USD 246 million by 2035 and grow at a 4.8% CAGR (2026-2035). Outpatient parenteral therapy and home-administered inhaled products extend use beyond inpatient settings, although patient selection and ongoing clinical supervision remain important constraints.
Other End Users
Other end users held a 15.0% share in 2025 and are projected to generate USD 383 million by 2035. Retail pharmacies and public-health procurement programs represent commercially different channels: the former is shaped by consumer-access products, while the latter relies on tenders and programmatic treatment priorities.
GMI Analyst View
We interpret segment performance as a move away from a single bulk-generic story toward a more segmented clinical portfolio. Hospital injectables remain fundamental, but the strongest differentiation lies in resistant urinary infections, respiratory delivery formats, neglected-disease procurement, and products with specialized administration or monitoring profiles.
Aminoglycosides Market Regional Analysis
North America Aminoglycosides Market Analysis
North America generated USD 710 million in 2025 and is projected to hold a 35.6% share by 2035. The aminoglycosides market in the region is supported by advanced hospital stewardship, established sterile-injectable purchasing systems, specialist respiratory care, and a comparatively mature outpatient treatment infrastructure.
U.S.
The U.S. generated USD 634 million in 2025 and is expected to account for 87.2% of North America by 2035. Demand is diversified across hospital injectables, specialty inhaled treatment, and outpatient therapy, while manufacturing concentration makes supply reliability a meaningful competitive attribute.
Canada
Canada is projected to generate USD 125 million by 2035 and grow at a 5.0% CAGR (2026-2035). Structured outpatient treatment programs and publicly supported specialty care create favorable conditions for monitored use beyond acute inpatient treatment.
Europe Aminoglycosides Market Analysis
Europe is projected to generate USD 574 million by 2035 and held a 22.0% share in 2025. Regional demand is underpinned by hospital stewardship, mature generic procurement, orthopedic use cases, and national health-system protocols that sustain controlled aminoglycoside utilization.
Germany
Germany generated USD 86 million in 2025 and is projected to grow at a 2.7% CAGR (2026-2035). Mature hospital purchasing and entrenched orthopedic and institutional applications support a stable market, though generic competition tempers revenue expansion.
UK
The UK is projected to generate USD 90 million by 2035 and grow at a 3.0% CAGR (2026-2035). Outpatient intravenous treatment infrastructure and structured antimicrobial governance support continued use in suitable community-linked care pathways.
France
France generated USD 67 million in 2025 and is expected to hold a 15.0% share of Europe by 2035. Hospital-based combination therapy and stewardship-led management of severe infections maintain demand for injectable formulations.
Italy
Italy is projected to generate USD 63 million by 2035 and held an 11.4% share in 2025. Regional formulary governance and the clinical management of resistant hospital pathogens support continued demand, particularly in tertiary-care settings.
Spain
Spain generated USD 38 million in 2025 and is projected to grow at a 3.2% CAGR (2026-2035). Public hospital formularies and institutional treatment of gram-negative infections provide the principal demand base.
Netherlands
The Netherlands is projected to generate USD 41 million by 2035 and held a 6.9% share in 2025. Established pharmacokinetic monitoring and outpatient treatment practices support a measured expansion in clinically governed use.
Rest of Europe
Rest of Europe is expected to hold a 22.7% share by 2035 and grow at a 4.1% CAGR (2026-2035). Healthcare investment and improving institutional antibiotic-management capacity create the main expansion pathway across this diverse group of markets.
Asia Pacific Aminoglycosides Market Analysis
Asia Pacific held a 30.0% share in 2025 and is projected to grow at a 4.3% CAGR (2026-2035). The aminoglycosides market in the region benefits from the interaction of tuberculosis burden, growing hospital capacity, domestic generic production, and the gradual formalization of prescribing governance.
China
China generated USD 173 million in 2025 and is expected to hold a 28.0% share of Asia Pacific by 2035. Centralized procurement sustains substantial utilization while constraining revenue realization, making price discipline and manufacturing efficiency central to supplier economics.
India
India is projected to generate USD 273 million by 2035 and grow at a 5.9% CAGR (2026-2035). Domestic treatment demand and a broad generic-manufacturing base create a distinctive demand-and-supply ecosystem, strengthening the country's importance in both local and export channels.
Japan
Japan accounted for 20.0% of Asia Pacific in 2025 and is projected to grow at a 1.8% CAGR (2026-2035). A mature healthcare market and comparatively limited infectious-disease growth constrain momentum, despite continued institutional demand for established therapies.
Australia
Australia is projected to generate USD 43 million by 2035 and held a 5.0% share in 2025. Strong clinical governance and monitored hospital prescribing support a stable market, complemented by specialist respiratory-care demand.
South Korea
South Korea generated USD 48 million in 2025 and is projected to grow at a 3.8% CAGR (2026-2035). Tertiary-care stewardship programs and domestic generic capability underpin structured demand across hospital formularies.
Rest of Asia Pacific
Rest of Asia Pacific is expected to hold a 12.2% share by 2035 and grow at a 6.5% CAGR (2026-2035). Rising hospital capacity and public procurement in high-burden infectious-disease markets create the region's strongest growth trajectory, although monitoring infrastructure remains uneven.
Latin America Aminoglycosides Market Analysis
Latin America is projected to generate USD 178 million by 2035 and grow at a 4.5% CAGR (2026-2035). Hospital investment, formalizing stewardship practices, and demand from public and private systems support growth, with procurement conditions varying widely by country.
Brazil
Brazil generated USD 48 million in 2025 and is projected to grow at a 4.8% CAGR (2026-2035). Public procurement and increasing stewardship adoption support institutional demand, while tender structures continue to influence pricing and supplier selection.
Mexico
Mexico is projected to generate USD 44 million by 2035 and held a 25.2% share of Latin America in 2025. Public health and social-security purchasing channels support injectable demand across a large hospital system.
Argentina
Argentina held a 16.5% share in 2025 and is projected to generate USD 26 million by 2035. Macroeconomic conditions and constrained healthcare spending moderate growth despite established clinical use in institutional settings.
Rest of Latin America
Rest of Latin America is expected to hold a 17.4% share by 2035 and grow at a 5.0% CAGR (2026-2035). Capacity expansion in hospitals and national treatment programs provides an avenue for increased purchasing across the region's smaller markets.
Middle East & Africa Aminoglycosides Market Analysis
Middle East & Africa is projected to generate USD 132 million by 2035 and held a 5.0% share in 2025. The region's outlook reflects contrasting demand environments: higher-value hospital procurement in Gulf markets and public-sector, tender-led purchasing across much of Sub-Saharan Africa.
South Africa
South Africa generated USD 29 million in 2025 and is projected to grow at a 2.5% CAGR (2026-2035). Tuberculosis treatment evolution and public-budget constraints limit expansion, even as the country retains a substantial need for infectious-disease therapies.
Saudi Arabia
Saudi Arabia is projected to generate USD 43 million by 2035 and held a 30.2% share of the region in 2025. Hospital investment and stewardship-led formulary management support demand for quality-assured injectable and specialty products.
UAE
The UAE is expected to hold a 22.0% share by 2035 and grow at a 4.3% CAGR (2026-2035). Advanced tertiary-care infrastructure and formal infection-management protocols support controlled, clinically targeted aminoglycoside use.
Rest of MEA
Rest of MEA held a 19.8% share in 2025 and is projected to grow at a 1.9% CAGR (2026-2035). Funding constraints, tender-driven pricing, and uneven monitoring capacity limit revenue growth despite persistent infectious-disease need.
GMI Analyst View
We expect Asia Pacific to command the greatest strategic attention because its growth is tied to more than population or disease burden. Expanding manufacturing depth, hospital formalization, and more structured stewardship can convert clinical need into sustainable procurement, while mature North American and European markets remain important for specialty formulations and dependable institutional demand.
Aminoglycosides Market Share & Competitive Landscape
The aminoglycosides market share structure is moderately concentrated, with the five leading suppliers holding a 43.0% combined share in 2025. Competition is defined by sterile-manufacturing capability, regulatory quality systems, hospital tender access, portfolio breadth, and the ability to balance low-cost generic supply with differentiated inhaled, ophthalmic, topical, or resistant-pathogen applications.
Fresenius Kabi held a 13.8% share in 2025. Its competitive position is supported by sterile-injectable scale, broad hospital supply relationships, and the operational importance of continuity in a category where shortages can quickly reshape procurement preferences.
Pfizer held a 10.2% share in 2025. The company combines broad hospital distribution capabilities with exposure to inhaled tobramycin, placing it across both conventional injectable demand and higher-value specialty respiratory treatment.
Aurobindo Pharma held a 7.0% share in 2025. Its vertically integrated generic model supports competitiveness in tenders and regulated international markets, where cost discipline, formulation availability, and compliance credentials determine commercial access.
Novartis, through Sandoz, participates through a generics platform with particular strength in European distribution and quality-sensitive hospital channels. Its positioning benefits from established experience in complex formulations and market access across institutional and retail settings.
Cipla has a meaningful role in India and export markets, particularly where institutional buyers and government procurement channels prioritize broad availability of generic formulations. Its AMR-oriented portfolio strategy may provide selective differentiation in resistance-driven indications.
Bausch Health Companies participates primarily through ophthalmic and topical products, where pharmacy distribution and eye-care relationships are more relevant than sterile-injectable scale. Teva Pharmaceuticals leverages broad generic infrastructure in competitive hospital channels, while Sun Pharmaceutical Industries benefits from strong Indian distribution and manufacturing reach.
Sanofi maintains selected branded-generic positions in European and emerging markets. Meiji Seika Pharma has relevance in Japan through domestic relationships and local supply, while Perrigo Company participates in consumer-oriented topical products. Kremoint Pharma serves cost-sensitive institutional and program-procurement markets with specialized generic capabilities.
Recent Industry Developments
GARDP Foundation acquired clinical research data and exclusive licensing rights for apramycin for human use in March 2026, reviving development activity around an aminoglycoside candidate with potential relevance to highly resistant gram-negative infections. The transaction may broaden the class's innovation pipeline if subsequent clinical work confirms a differentiated safety and resistance profile [6]GARDP Foundation. "GARDP revives clinical research into apramycin as potential treatment for life-threatening 'superbugs'." gardp.org.
Russia's Vostok facility launched full-cycle tobramycin production in the Kirov region in August 2026, covering active pharmaceutical ingredient production and finished dosage manufacturing. The development highlights the strategic importance that national supply-security initiatives assign to antibiotic capacity, particularly for hospital and respiratory-care products [7]GxP News. "Russia launches full-cycle production of strategic antibiotic tobramycin in Kirov region." gxpnews.net.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →